Moreover, we studied their reactions with different reagents optimistically to synthesize novel organoselenium compounds incorporating selenopyridine moiety and assessed the sensitivity of prostate cancer and osteosarcoma cell lines to synthesized compounds compared with Doxorubicin, standard chemotherapy using an EGFR activity inhibitory assay. Here, EGFR is linked to prostate carcinoma.